skip to main |
skip to sidebar
Web
xcovery.blogspot.com
Kinase Industry Biz News
Links
Blog Roll
Kinase efforts you may not know of
Blog Archive
-
▼
2006
(54)
-
▼
November
(34)
- Pfizer's pipeline
- TT: patient base expands beyond payment capacity?
- Interesting reading: next 50 years of science (New...
- ARRY's p38
- Rational DD vs. Trial & error (HTS)
- Gleevec for RA?
- Pathway focused discovery
- Survey of technology facilitating kinase inhibitor...
- Small companies, small molecules
- No title
- Bio business food chain in action
- ALL therapies: +12% for next 9 years
- Lilly: postive P3 Arxxant results
- Targeted Cancer Drugs May Work By Disrupting Balan...
- Are EGFR Inhibitors Only Useful in Certain Patient...
- UPDATE: Tykerb
- Tykerb: $2B in rev @ peak?
- This time anti-inflammatory has anti-cancer effect
- Cancer kinase inhibitors for hypertension too?
- Tarceva in the news
- MP-529 (Supergen)
- Handicapping targeted drugs
- CYC116
- Kinase drug discovery 101
- BI touts new multi-TK inhibitors
- PI3 summary
- Nexavar vs. Sutent
- Proposal to reduce GMP requirement for P1 trials d...
- Company with PI-3 compound under development sold
- Ambit + Cephalon= $250M
- AMG 706: not so hot
- AMG 706 news
- Exelexis suspends XL999 P2 trials
- Citation for level of pharma kinase activity
-
▼
November
(34)
Google search
Sitemeter
Technorati
clustermap
Cloud
Labels
- 2007 (1)
- ABT-737 (1)
- Accelrys (1)
- access (1)
- Akt (2)
- ALL (2)
- Alliances (1)
- Ambit (1)
- AMG 706 (2)
- AMGN (1)
- AML (1)
- Amphora (1)
- Ariad (1)
- ARRY (4)
- ARRY-543 (1)
- ARRY-797 (1)
- Arxxant (1)
- Aurora (2)
- Avastin (3)
- Aveon (1)
- Axitinib (1)
- Axl (1)
- AZ (1)
- basics (1)
- Bayer (2)
- Bcr-abl (1)
- BI (1)
- BI-2536 (1)
- BIBF-1120 (1)
- BIBW-2992 (1)
- Biomira (1)
- BMS (4)
- BREL (1)
- business models (1)
- cancer (2)
- CDK4 (2)
- Celebrex (1)
- Cephalon (1)
- CGI (1)
- chemo (1)
- CML (1)
- CML NVS (1)
- cool (2)
- Cox-2 (1)
- CP-690550 (1)
- CP-751871 (1)
- Curagen (1)
- CYC116 (1)
- Cyclacel (3)
- discovery (1)
- DNA (10)
- EGFR (3)
- erb-b2 (2)
- Exelixis (2)
- finance (1)
- Flt-3 (1)
- Gleevec (5)
- GSK (2)
- HDI (1)
- herceptin (2)
- Icahn (1)
- IGFR-1 (1)
- IKK (1)
- IMC-3G3 (1)
- IMCL (4)
- inflammation (1)
- Innovive (1)
- IPO (1)
- Iressa (1)
- IVGN (1)
- JAK2 (1)
- Jak3 (2)
- Kit (1)
- Lilly (1)
- lung (1)
- M+ A (1)
- Market stats (1)
- MDACC (1)
- MEDI (1)
- Mek (1)
- Merck (1)
- Merrimack (1)
- Met (2)
- MK-0457 (1)
- mutations (1)
- new targets (2)
- Nexavar (5)
- NVS (3)
- ONXX (5)
- OSIP (3)
- OSU-03012 (1)
- P3 (1)
- p38 (4)
- Pathways (1)
- PCOP (1)
- PDGFR (2)
- pertuzumab (2)
- PFE (3)
- PI3 (3)
- Pim (1)
- PKC (1)
- Plk (1)
- ProIX (1)
- prostate (1)
- RA (3)
- RCC (3)
- Sanofi (1)
- Scios (1)
- SGX (3)
- SGX-523 (2)
- SNS-032 (1)
- Sprycel (1)
- Src (1)
- Sunesis (1)
- SUPG (1)
- Sutent (5)
- TAK1 (1)
- Tarceva (3)
- Targegen (1)
- Targeted therapies (1)
- Tasigna (1)
- thyroid (1)
- Torisel (1)
- trials (1)
- Tykerb (3)
- VEGF (2)
- VEGFR (1)
- VRTX (1)
- VX-680 (1)
- WYE (1)
- Wyeth (1)
- Xcovery (1)
- XL518 (1)
- XL999 (1)
Feeds
1 comment:
That may be all true and nice but the passivists, slobs and cynics have more fun.
Post a Comment